Last reviewed · How we verify
Standard empirical antimicrobial treatment discontinuation
This is a clinical protocol for discontinuing empirical broad-spectrum antimicrobial therapy based on standardized criteria rather than a pharmacological drug.
This is a clinical protocol for discontinuing empirical broad-spectrum antimicrobial therapy based on standardized criteria rather than a pharmacological drug. Used for De-escalation of empirical antimicrobial therapy in hospitalized patients with suspected or confirmed infections.
At a glance
| Generic name | Standard empirical antimicrobial treatment discontinuation |
|---|---|
| Also known as | Laboratory rules for finalization of antimicrobial therapy |
| Sponsor | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Antimicrobial Stewardship |
| Phase | FDA-approved |
Mechanism of action
This represents a therapeutic strategy or clinical guideline for de-escalation of antimicrobial treatment in hospitalized patients, rather than a specific drug entity. It involves stopping or narrowing empirical antibiotic coverage when clinical and microbiological criteria are met, reducing unnecessary antibiotic exposure and supporting antimicrobial stewardship.
Approved indications
- De-escalation of empirical antimicrobial therapy in hospitalized patients with suspected or confirmed infections
Common side effects
Key clinical trials
- Early Versus Late Stopping of Antibiotics in Adults With High-risk Hematological Malignancies/Receiving Cellular Therapies and Fever (NA)
- Presepsin to Safely Reduce Antibiotics in Preterm Infants (NA)
- Rapid De-escalation of Anti-MRSA Therapy Guided by S. Aureus Nares Screening in Case of Pneumonia (NA)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- DiagNostic Study of Low-dose CT and multipleX PCR on Antibiotic Treatment and Outcome of Community-Acquired Pneumonia (NA)
- Study to Reduce Duration of Antibiotic Therapy in Haematological Patients With Fever and Neutropenia (PHASE4)
- Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: